CTOs on the Move

Delfi Diagnostics

www.delfidiagnostics.com

 
Delfi is developing a new class of liquid biopsy tests for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells. By applying advanced machine learning algorithms, these fragment patterns are detectable at a very low sequencing cost. Delfi is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Tobias Mann
 Vice President of Software Engineering and Information Technology Profile
Timothy McDaniel
 Vice President of Technology Development Profile

Funding

Delfi Diagnostics raised $100M on 01/12/2021

Similar Companies

parteqinnovations

parteqinnovations is a Kingston, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Santurus

Santurus is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

WindMIL Therapeutics

WindMIL Therapeutics is a clinical stage oncology cell therapy company. We are leveraging our proprietary platform to develop a novel class of cell therapies called MILs™ (Marrow Infiltrating Lymphocytes) derived from memory T cells found in the bone marrow.

ImClone Systems

ImClone Systems is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Elan

Elan is a biotechnology company, headquartered in Ireland, committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world.